What is the appropriate antibiotic management for a wound that was initially positive for Escherichia coli and is now positive for Pseudomonas aeruginosa while the patient is receiving ertapenem?

Ertapenem Must Be Discontinued and Replaced with an Antipseudomonal Agent

Ertapenem has no activity against Pseudomonas aeruginosa and will not treat this infection—immediate antibiotic change is mandatory. 1

Critical Gap in Coverage

Ertapenem lacks coverage for Pseudomonas aeruginosa, which is now the dominant pathogen in this wound. The FDA label explicitly states that ertapenem is inactive against P. aeruginosa, making continuation futile and potentially harmful through delayed appropriate therapy. 1, 2

• Ertapenem's spectrum limitation: While effective against E. coli and most Enterobacterales, ertapenem demonstrates "limited activity against Enterococcus spp., Pseudomonas aeruginosa and other nonfermentative Gram-negative bacteria." 2
• No cross-selection concern: Ertapenem use does not increase resistance to antipseudomonal carbapenems (imipenem, meropenem, doripenem), so switching is safe from a resistance perspective. 3

Recommended Antibiotic Switch

For non-carbapenem-resistant Pseudomonas aeruginosa, initiate piperacillin-tazobactam 3.375-4.5g IV every 6 hours as first-line therapy. 4

Treatment Algorithm Based on Susceptibility:

If susceptibilities are available and organism is susceptible to standard agents:

• Piperacillin-tazobactam 3.375-4.5g IV q6h (preferred for wound infections) 4
• Ceftazidime 2g IV q8h 4
• Cefepime 2g IV q8-12h 4
• Ciprofloxacin 400mg IV q8h 4
• Levofloxacin 750mg IV daily 4

If difficult-to-treat or carbapenem-resistant P. aeruginosa (DTR-PA/CRPA):

• Ceftolozane-tazobactam 1.5-3g IV q8h 4
• Ceftazidime-avibactam 2.5g IV q8h 4
• Colistin (with or without combination therapy) if no other options 4

Duration of Therapy:

• Wound infections: 5-10 days for uncomplicated cases 4
• Complicated skin/soft tissue infections: 7-14 days based on clinical response 4

Combination Therapy Considerations

For severe wound infections with DTR-PA, consider combination therapy with two active agents. 4

• The ESCMID guidelines suggest combination therapy when treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin. 4
• For new beta-lactam/beta-lactamase inhibitors (ceftolozane-tazobactam, ceftazidime-avibactam), monotherapy is acceptable if the organism is susceptible. 4
• Aminoglycosides should not be used as monotherapy except for urinary tract infections. 4

Common Pitfalls to Avoid

Do not continue ertapenem hoping for "partial coverage"—it provides zero activity against Pseudomonas. 1, 2

• Delayed appropriate therapy increases mortality and morbidity in wound infections, particularly with P. aeruginosa which can rapidly progress. 5
• P. aeruginosa and S. aureus co-infections are more virulent than single infections—ensure adequate coverage if both organisms persist. 5
• Obtain susceptibility testing immediately to guide definitive therapy and avoid empiric broad-spectrum agents if narrower options are available. 4

Clinical Monitoring

Reassess wound clinically within 48-72 hours of antibiotic change to confirm treatment response.

• Look for reduction in purulence, erythema, warmth, and pain at the wound site
• Repeat wound cultures if clinical deterioration occurs or if no improvement by 72 hours 4
• Monitor for development of resistance during therapy, particularly with fluoroquinolones and cephalosporins used as monotherapy 6